AUS
NZ
UK
CA
USA
IND
The Wellcome Trust, with its £36.8 billion ($72 billion) endowment, has demonstrated how a strategic, long-term approach can yield impressive results. Under the leadership of Chief Investment Officer Nick Moakes, the Trust has turned what might seem like a conventional financial move into a pioneering strategy with substantial benefits.
Strategic Bonds and Low Rates: A Financial Masterstroke
In a period of unprecedentedly low interest rates, the Wellcome Trust executed a remarkable financial strategy. In 2018, the Trust issued a £750 million, 100-year bond, and followed it up with a similar £750 million, 50-year bond in 2021. The interest rates secured were notably low, at just 2.5% and 1.5%, respectively. These rates are significantly lower than those prevailing in the broader market, reflecting a keen awareness of the financial landscape at that time.
Moakes describes this period as a “moment in time” for the Trust, highlighting that the fixed-income assets were “eye-wateringly overvalued.” While these bonds now trade at lower values—around 39¢ and 50¢ on the dollar—due to rising interest rates and the lengthy payment period, the Trust’s decision to lock in low rates has proven to be highly advantageous. This approach has “created vast amounts of value,” according to Moakes.
A Legacy of Generosity and Innovation
The Wellcome Trust, founded in 1936 with the wealth of pharmaceutical magnate Henry Wellcome, is one of the largest financial supporters of scientific research in the United Kingdom. Since Moakes joined the Trust in 2007 and became CIO in 2017, the Trust’s assets have grown from £15.1 billion to £36.8 billion. Over £15 billion has been allocated to health-related scientific projects globally, including significant contributions to Australian research.
In December 2023, the Trust awarded $5.4 million to a research team at the University of Sydney to study the impact of disruptive sleep patterns on mental health. Just a month later, $4.9 million was granted to the University of Melbourne to investigate the effects of climate change on farmers in Kyrgyzstan.
Governance and Risk Management: A Balanced Approach
Moakes emphasizes that the Trust’s unique position—without external clients—provides a significant advantage. However, this does not simplify the task of managing such a substantial portfolio. The Trust must balance risk while maintaining liquidity to respond to urgent funding needs for scientific breakthroughs. This requires rigorous governance to ensure the best decisions are made.
Moakes’ long-term perspective is central to the Trust’s strategy. He advocates for investing with a 50-year horizon, focusing on real assets that can appreciate with nominal GDP growth. This philosophy helps shield the Trust from inflationary pressures and aligns with a broader investment approach that prioritizes sustainability and growth.
Navigating the Modern Financial Landscape
Moakes is critical of the traditional funds management model, which he refers to as the “tyranny of benchmarks.” In today’s market, where a few dominant tech companies like [Nvidia] (NASDAQ:NVDA), [Apple] (NASDAQ:AAPL), and [Amazon] (NASDAQ:AMZN) significantly influence indices, focusing exclusively on these stocks can be risky. Moakes argues that relying solely on such companies for portfolio performance can expose investors to substantial risks if market dynamics shift.
The Trust’s approach to private equity and venture capital also reflects a forward-thinking mindset. Despite a 10.4% decline in its £12.8 billion private equity portfolio due to venture-related revaluations last year, Moakes remains optimistic. He believes that innovation drives economic growth and that early-stage ventures are essential for future returns.
Hedge Funds and Cash Holdings: A Diversified Strategy
The Trust’s allocation to hedge funds aims to leverage expertise and risk management beyond traditional investment strategies. Although the proportion of assets allocated to hedge funds decreased from 23% in September 2008 to around 10% by the end of the last financial year, this reflects a careful assessment of their relative performance and fees.
On the other hand, the Trust holds approximately 9% of its assets in cash, a significant portion given the low interest rates achieved with the long-term bonds. While cash holdings typically act as a drag on returns, the current UK overnight cash rate of 5% presents a notable opportunity compared to the 100-year rates secured previously.
Looking Ahead
As the Wellcome Trust continues to evolve under Moakes’ leadership, its strategies serve as a testament to the benefits of long-term planning and strategic financial management. The Trust’s investments in research and its careful balance of asset allocation reflect a commitment to making a lasting impact on global health and scientific advancement.
Moakes’ legacy, marked by thoughtful investment decisions and a focus on innovation, underscores the value of a long-term perspective in navigating the complexities of modern finance.
